Loading...
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.
Cameron, D Morden, J Canney, P Velikova, G Coleman, R Bartlett, J Agrawal, R Banerji, J Bertelli, G Bloomfield, D
Cameron, D
Morden, J
Canney, P
Velikova, G
Coleman, R
Bartlett, J
Agrawal, R
Banerji, J
Bertelli, G
Bloomfield, D
Citations
Altmetric:
Abstract
Adjuvant chemotherapy for early breast cancer has improved outcomes but causes toxicity. The UK TACT2 trial used a 2×2 factorial design to test two hypotheses: whether use of accelerated epirubicin would improve time to tumour recurrence (TTR); and whether use of oral capecitabine instead of cyclophosphamide would be non-inferior in terms of patients' outcomes and would improve toxicity, quality of life, or both.
Description
Date
2017-07
Publisher
Collections
Files
Loading...
CORE by link
Adobe PDF, 721.68 KB
Keywords
Type
Article
Citation
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. 2017, 18 (7):929-945 Lancet Oncol